Explore how Tetraphase is developing novel antibiotics accessible to all at-risk patients in need.
Location: United States, Massachusetts, Watertown
Total raised: $55M
Founded date: 2006
Investors 4
| Date | Name | Website |
| - | F-Prime Ca... | fprimecapi... |
| - | Excel Vent... | excelvm.co... |
| - | Eight Road... | eightroads... |
| - | Bay City C... | baycitycap... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 01.06.2010 | Series C | $45M | - |
| 06.10.2009 | - | $10M | - |
Mentions in press and media 12
| Date | Title | Description |
| 16.03.2020 | AcelRx Pharmaceuticals to Acquire Tetraphase Pharmaceuticals | AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a Redwood City-based specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, is to acquire Tetraphas... |
| 16.03.2020 | Another antibiotic maker bites the dust, as Tetraphase is swallowed for cheap | Some four years after it reported its first batch of pivotal trial data, Tetraphase finally secured FDA approval for its lead antibiotic, eravacycline, for complicated intra-abdominal infections in 2018. But like ma... |
| 30.03.2017 | CARB-X dishes out $48M in grants to antimicrobial startups | Launched in mid-2016, CARB-X stands for Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator. It comes in response to the growing threat of drug-resistant infections — and the concerning lack of late-stage antibacterial dru... |
| 25.11.2015 | Drug industry warming to antibiotics, but resistance outpaces new products | Kendall Squared brings you dispatches from the world’s epicenter for biotechnology and drug discovery. When Dr. Ankit Mahadevia founded Spero Therapeutics in 2013 to discover new antibiotics, he thought he would encounter some doubters. Tho... |
| 26.03.2015 | Flagship Ventures raises $537M in new fund; plans to launch 5 companies per year | The company’s previous fund was $269 million. Some of its more successful exits during this biotech boom have been the IPOs of Receptos, Agios Pharmaceuticals, Tetraphase Pharmaceuticals and Acceleron Pharma. Other notable companies that re... |
| 18.12.2014 | Tetraphase Announces Positive Top-line Results from Phase 3 IGNITE 1 Clinical Trial of Eravacycline | Watertown, MA — Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced positive top-line result... |
| 06.03.2013 | Antibiotics outfit Tetraphase offers price range for $75M biotech IPO | Tetraphase Pharmaceuticals hopes that the next phase for the biotech is as a public company. Toward that end, the Watertown, MA-based antibiotics developer plans an IPO of just over 6.8 million shares of common stock at a proposed price ran... |
| 15.09.2010 | Tetraphase Shows What the $45M Was All About at Big Antibiotics Conference | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Tetraphase Pharmaceuticals raised a big $45 million venture round back in June, and now scientists can see more clearly why it’s been able to raise all that dough. The Waterto... |
| 01.06.2010 | Tetraphase Pharmaceuticals Raises $45M in Series C financing | Tetraphase Pharmaceuticals, a Watertown, MA-based clinical stage biopharmaceutical company utilizing a synthetic chemistry technology to discover and develop innovative antibiotics, has raised $45m in a Series C financing. The round was led... |
| 06.10.2009 | Tetraphase Pharmaceuticals Raises $10M to close first tranche of $25M Financing | Watertown, MA-based Tetraphase Pharmaceuticals Inc., which focuses on discovering novel antibiotics to treat drug-resistant infections, has closed the first tranche of its $25m Series B financing. The funds will support the advancement of s... |
Show more